The University of Southampton
University of Southampton Institutional Repository

Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications

Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications
Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications
Context: Nonalcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and is the most common chronic liver disease in Western countries. In this review, we discuss the role of NAFLD as a novel cardiometabolic risk factor for the development of type 2 diabetes (T2DM) and for the development of major chronic complications and poor glycemic control in people with established T2DM.

Evidence Acquisition: This is a clinical, narrative review and not a systematic review and meta-analysis. PubMed was extensively searched for articles using the keywords “nonalcoholic fatty liver disease” or “fatty liver” combined with “diabetes risk,” “cardiovascular risk,” “cardiovascular mortality,” “chronic kidney disease,” or “diabetic nephropathy” between 1990 and 2012. Articles published in languages other than English were excluded from the analysis.

Evidence Synthesis: NAFLD exacerbates hepatic insulin resistance and increases the risk of developing T2DM. Growing evidence also indicates that NAFLD may worsen glycemic control in people with T2DM and may contribute to the development and progression of the most important chronic complications of diabetes, such as cardiovascular disease and chronic kidney disease.

Conclusions: The adverse impact of NAFLD on risk for T2DM and its major chronic vascular complications deserves particular attention among endocrinologists/cardiologists/hepatologists, in view of the implications for screening and surveillance strategies in the growing number of patients with NAFLD. Clinicians who manage patients with NAFLD should not only focus on liver disease, but should also recognize the increased risk of developing T2DM and its chronic vascular complications and undertake early, aggressive risk factor modification.

0021-972X
483-495
Targher, G.
5a842bd2-91c4-4063-b639-da6c681f3698
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Targher, G.
5a842bd2-91c4-4063-b639-da6c681f3698
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c

Targher, G. and Byrne, Christopher D. (2013) Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology & Metabolism, 98 (2), 483-495. (doi:10.1210/jc.2012-3093). (PMID:23293330)

Record type: Article

Abstract

Context: Nonalcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and is the most common chronic liver disease in Western countries. In this review, we discuss the role of NAFLD as a novel cardiometabolic risk factor for the development of type 2 diabetes (T2DM) and for the development of major chronic complications and poor glycemic control in people with established T2DM.

Evidence Acquisition: This is a clinical, narrative review and not a systematic review and meta-analysis. PubMed was extensively searched for articles using the keywords “nonalcoholic fatty liver disease” or “fatty liver” combined with “diabetes risk,” “cardiovascular risk,” “cardiovascular mortality,” “chronic kidney disease,” or “diabetic nephropathy” between 1990 and 2012. Articles published in languages other than English were excluded from the analysis.

Evidence Synthesis: NAFLD exacerbates hepatic insulin resistance and increases the risk of developing T2DM. Growing evidence also indicates that NAFLD may worsen glycemic control in people with T2DM and may contribute to the development and progression of the most important chronic complications of diabetes, such as cardiovascular disease and chronic kidney disease.

Conclusions: The adverse impact of NAFLD on risk for T2DM and its major chronic vascular complications deserves particular attention among endocrinologists/cardiologists/hepatologists, in view of the implications for screening and surveillance strategies in the growing number of patients with NAFLD. Clinicians who manage patients with NAFLD should not only focus on liver disease, but should also recognize the increased risk of developing T2DM and its chronic vascular complications and undertake early, aggressive risk factor modification.

This record has no associated files available for download.

More information

Published date: February 2013
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 348432
URI: http://eprints.soton.ac.uk/id/eprint/348432
ISSN: 0021-972X
PURE UUID: be6c275f-2a27-4929-99cb-6ab23b34f49b
ORCID for Christopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 13 Feb 2013 11:57
Last modified: 23 Jul 2022 01:45

Export record

Altmetrics

Contributors

Author: G. Targher

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×